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Is increased antidepressant exposure a contributory factor to
the obesity pandemic?
SH Lee1, G Paz-Filho1, C Mastronardi1, J Licinio2 and M-L Wong2
Major depressive disorder (MDD) and obesity are both common heterogeneous disorders with complex aetiology, with a major
impact on public health. Antidepressant prescribing has risen nearly 400% since 1988, according to data from the Centers for
Disease Control and Prevention (CDC). In parallel, adult obesity rates have doubled since 1980, from 15 to 30 percent, while
childhood obesity rates have more than tripled. Rising obesity rates have signiﬁcant health consequences, contributing to increased
rates of more than thirty serious diseases. Despite the concomitant rise of antidepressant use and of the obesity rates in Western
societies, the association between the two, as well as the mechanisms underlying antidepressant-induced weight gain, remain
under explored. In this review, we highlight the complex relationship between antidepressant use, MDD and weight gain. Clinical
ﬁndings have suggested that obesity may increase the risk of developing MDD, and vice versa. Hypothalamic–pituitary–adrenal
(HPA) axis activation occurs in the state of stress; concurrently, the HPA axis is also dysregulated in obesity and metabolic
syndrome, making it the most well-understood shared common pathophysiological pathway with MDD. Numerous studies have
investigated the effects of different classes of antidepressants on body weight. Previous clinical studies suggest that the tricyclics
amitriptyline, nortriptyline and imipramine, and the serotonin norepinephrine reuptake inhibitor mirtazapine are associated with
weight gain. Despite the fact that selective serotonin reuptake inhibitor (SSRI) use has been associated with weight loss during
acute treatment, a number of studies have shown that SSRIs may be associated with long-term risk of weight gain; however,
because of high variability and multiple confounds in clinical studies, the long-term effect of SSRI treatment and SSRI exposure on
body weight remains unclear. A recently developed animal paradigm shows that the combination of stress and antidepressants
followed by long-term high-fat diet results, long after discontinuation of antidepressant treatment, in markedly increased weight, in
excess of what is caused by high-fat diet alone. On the basis of existing epidemiological, clinical and preclinical data, we have
generated the testable hypothesis that escalating use of antidepressants, resulting in high rates of antidepressant exposure, might
be a contributory factor to the obesity epidemic.
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INTRODUCTION
Major depressive disorder (MDD) and obesity are both common,
heterogeneous disorders with complex aetiology, and pro-
nounced public health impact.1,2 According to data from the
World Health Organization (WHO), MDD has become the second
most prevalent cause of illness-induced disability, affecting 350
million people worldwide.3 In the United States, costs related to
MDD such as medical expenses are estimated to be $210.5 billion
a year.4,5 With a lifetime prevalence of 16.2%, MDD is twice as
common in women. Moreover, two-thirds of suicides are
associated with MDD.1 In Australia, according to the 2011–2012
National Survey of Mental Health and Wellbeing, 9.7% of people
aged 16–85 years were affected by mood disorders.6 In Europe, 1
out of 15 people are known to suffer from MDD.7
Concomitantly, obesity is a debilitating epidemic affecting
34.9% of US adults (78.6 million individuals), resulting in estimated
annual medical costs of $147 billion in 2008.8 Since 1962, the
prevalence of obesity among adults more than doubled, from 13.4
to 35.7% among American adults aged 20 and older,9 in a manner
that parallels the increase in MDD treatment. Besides type 2
diabetes mellitus and cardiovascular diseases (CVDs), obesity has
other disabling consequences, including cancer,10 sleep
disorders11 and psychological distress.12 In the past few decades,
studies have addressed the relationship between obesity and
MDD.13–18 Previous clinical ﬁndings have suggested that obesity
could increase the risk of developing MDD, and vice versa.19–24 It
has been suggested that obesity and MDD share common
pathophysiology to a certain extent, yet the precise pathways
and mechanisms for a causal association between MDD and
obesity remain unknown.
In United States of America, over the past two decades, the rate
of antidepressant use has increased nearly 400%, where
antidepressant drugs were the third most prescribed class of
drugs for persons aged 18-44 years in 2005–2008.25 In 2010, it was
reported that 52.3 daily doses were prescribed for every 1000
inhabitants in European countries.26 In Australia, 34 million
prescriptions were issued for mental health-related diseases in
2013–2014, and 67% (23 million) of those were for
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antidepressants.27 In 2012–2013, mental health-related prescrip-
tions cost the Australian Government over $788 million.27 With a
rapid rise of individuals taking antidepressants, numerous studies
have investigated the effects of different classes of antidepres-
sants on body weight. Despite the concomitant occurrence of the
frequent use of antidepressants and the high incidence of obesity
in Western societies, the pathways and mechanisms by which
antidepressants can induced weight gain remain unclear.
In this review, we examine the pathophysiology of MDD and
obesity, and their complex interactions. More speciﬁcally, we
discuss the role of antidepressant use in weight gain, and the role
of interactions with environmental factors, such as stress.
MDD
The diagnosis of MDD is made in the presence of ﬁve or more of
the following symptoms for a continuous 2-week period or longer,
as described in the Diagnostic and Statistical Manual of Mental
Disorders (DSM-5): (i) depressed mood most of the day, nearly
every day; (ii) signiﬁcant weight loss/gain or decrease/increase in
appetite; (iii) markedly diminished interest or pleasure in almost all
activities; (iv) insomnia or hypersomnia; (v) fatigue or loss of
energy; (vi) psychomotor retardation or agitation; (vii) feelings of
worthlessness; (viii) diminished ability to concentrate or make
decisions; and (ix) recurrent thoughts of death.28 MDD is a
complex disorder; its exact pathophysiology remains elusive, as
does the mechanism of action of antidepressants. Over many
decades, the pathophysiology of MDD was thought to be based
on the hypothesis of monoamine depletion, supported by the fact
that the monoamine oxidase inhibitors (MAOIs), a class of
antidepressants, restored physiological levels of monoamine in
the brain.29 Although monoamine levels can be restored acutely,
within a few hours after treatment, full antidepressant action is
achieved only after 3–4 weeks of treatment initiation. This gap
between immediate biochemical effects and delayed clinical
response fostered the development of new theories for the
pathophysiological mechanism of MDD that go beyond the
monoamine hypothesis.
Other theories for the underlying biology of MDD include the
neuroendocrine, neuroimmune and neurotropic hypotheses.29,30
The neuroendocrine theory proposes that the pathophysiological
mechanism of MDD involves abnormal homeostasis of the
hypothalamus–pituitary–adrenal (HPA) axis, with overactivation
of the stress response.30,31 Cortisol levels are often increased in
the plasma of MDD patients,30,32 and antidepressant treatment
downregulates the HPA axis response.30 Moreover, recent
evidence points towards the importance of insulin-like growth
factor 1 in MDD.33–36 It has been suggested that, in mice, insulin-
like growth factor 1 deﬁciency is accompanied by impaired adult
hippocampal neurogenesis and decreased total number of
neurons in the hippocampus.33 In a mouse model, administration
of insulin-like growth factor 1 via intracerebroventricular injection
has an antidepressant-like action in rodents.33–36 Furthermore, it
has been observed that the adipose tissue-derived hormone
leptin has a potential role in MDD: circulating leptin levels are
decreased in MDD patients and in individuals who attempt
suicide, in comparison with healthy controls.37–40 In contrast, the
relationship between antidepressant treatment and leptin levels
remains less clear. Schilling et al. have shown that amitriptyline or
mirtazapine antidepressant treatment increased plasma leptin
concentrations, whereas the plasma leptin level remained
unaltered with paroxetine and venlafaxine treatments.41 Further-
more, intrahippocampal, but not intrahypothalamic administration
of leptin led to antidepressant-like action in rodents, suggesting
that leptin-induced antidepressant actions were not secondary to
leptin-induced metabolic effects.42
The neuroimmune theory proposes that immune mediators
such as cytokines (e.g., interferons and interleukins) may have a
role in MDD.30 As those immune mediators modulate key
functions such as sleep, appetite, cognition and temperature
regulation, any alterations in those mediators can contribute
indirectly to the pathogenesis of MDD, by disrupting vital
functions.30 That theory is substantiated by the observation that
the innate immune system is altered in MDD towards a pro-
inﬂammatory state, and by the fact that some antidepressants act
by reducing inﬂammation via cyclooxygenase inhibition.
In addition, cytokines can contribute to HPA axis hyperactivity,
and affect the serotonergic, dopaminergic, glutamatergic and
monoamonergic systems, contributing to MDD.43 Accordingly,
pro-inﬂammatory cytokines stimulate glucocorticoid release by
acting at all three levels of the HPA axis: at the paraventricular
nucleus level, they stimulate the release of corticotropin-releasing
hormone (CRH) level; at the pituitary level, they stimulate the
release of adrenocorticotropin; and at the adrenal glands, they
stimulate the release of glucocorticoids.
The neurotropic theory is a newer hypothesis for MDD, and it
proposes that antidepressant treatment leads to acute restoration
of monoamine levels in the brain, followed by changes in
neuroplasticity via increased synaptic contacts and dendritic
arborisation.44 The neurotropic hypothesis implies that neuro-
tropic factors are the key factors in antidepressant action.29 These
include the nerve growth factor (NGF) and the neurokine or
neuropoetin superfamilies. The NGF superfamily includes NGF,
brain-derived neurotropic factor (BDNF), neurotrophin-3 and
neurotrophin-6. The antidepressant effect via BDNF has important
roles in supporting neuronal survival and maintaining
neuroplasticity.45 In rodent models of stress-induced depression,
lower levels of BDNF in the hippocampus were restored by
antidepressant treatment.44,46 Furthermore, antidepressant treat-
ments have failed to elevate hippocampal neurogenesis at the
subgranular zone in a mouse model of absence of BDNF–tyrosine
receptor kinase B (BDNF-TrkB) signalling.47 Consequently, neuro-
tropic factors, such as BDNF, may have an important role in the
mechanism of antidepressant action.
OBESITY
Obesity is primarily deﬁned as the excess of fat mass of sufﬁcient
magnitude to produce adverse health consequences. It is
diagnosed based on total body weight in relation to height (that
is, body mass index (BMI) of 30 kg/m2 and over), whereas
overweight is diagnosed in the presence of BMI between 25
and 29.9 kg/m2.48 As those diagnostic criteria do not take into
account fat content, other measures of adiposity can also be used
for the proper assessment of metabolic risk, such as waist
circumference, waist-to-hip ratio, total body fat and body fat
percentage. By employing those measures, one can identify
individuals with normal body weight and excessive fat content
('metabolically obese, normal weight'), who are also at risk for
metabolic diseases. The overly reductionistic explanation of the
pathophysiology of obesity as solely due to energy imbalance
resulting from excessive food intake and insufﬁcient energy
expenditure has evolved over time to become more nuanced. It is
now known that the causes of obesity are complex, and many
factors including environment, genetics, culture, food choices and
hormonal factors contribute to obesity.49
Obesity is one component of a cluster of risk factors that
increases the risk for the development of type 2 diabetes mellitus
and CVD, known as metabolic syndrome (MetS).50 There is no
consensus regarding the diagnosis of MetS; however, in 2009, a
joint statement by various medical organisations was published,
stating that obesity and insulin resistance are not prerequisites for
MetS; three of the ﬁve following components would sufﬁce for a
diagnosis of MetS: elevated waist circumference (a measure of
visceral obesity), high blood pressure (or antihypertensive drug
treatment in a patient with a history of hypertension), high fasting
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hyperglycaemia (or drug treatment of elevated glucose), elevated
triglycerides (or drug treatment for elevated triglycerides) and
reduced high-density lipoprotein (HDL)-cholesterol (or drug
treatment for reduced HDL-cholesterol).51
MDD AND OBESITY
Obesity and MDD have in common several biological aspects, as
described by Bornstein et al.52 Both disorders frequently co-exist,
causing substantial health problems. However, those disorders
sometimes do not occur concurrently; obesity can follow
depression that occurred earlier in life. On the one hand,
depressed mood can be a side effect of obesity treatments,
which is further confounded by changes in lifestyle. On the other
hand, weight gain can be a side effect of antidepressant
treatments. From the pathophysiological point of view, the
regulation of mood and body weight is characterised by shared
neuropeptidergic and neurotransmitter systems, such as CRH,
neuropeptide Y (NPY), serotonin and norepinephrine. Both
disorders can lead to CVD, and genetic polymorphisms may
underlie the predisposition both to CVD and to depression. Finally,
most drugs used in depression and in obesity predominantly
affect either serotonin or norepinephrine.
In the past few decades, studies have addressed the relationship
between obesity and MDD, and they have suggested that both
disorders share a common pathophysiology to a certain extent.
However, because of the heterogeneity of clinical data and the
methodology used in different studies, variations do exist across
studies. Cross-sectional and longitudinal studies have been
conducted in order to understand the casual relationship between
MDD and obesity, and vice versa.13–18 Several studies have
pinpointed that obesity is positively associated with MDD. In the
cross-sectional study conducted by Rosmond et al., waist
circumference (a measure of visceral adiposity) was associated
with symptoms of MDD among Swedish men.13 In another study,
obesity was associated with increased risk for affective disorders in
a cluster sample of young German women.15 In the third National
Health and Nutrition Examination Survey (NHANES-III), obese
individuals with BMI440 were more likely to suffer from MDD
than individuals with BMI of 30–34.9 kg/m2.16 In longitudinal
studies with a 5-year follow-up, obese individuals had an increased
odds ratio of 2.13 for MDD, indicating that obese individuals are
twice as likely to suffer from MDD in comparison with non-obese
individuals.17 Another study suggested that obesity is associated
with an ~ 25% increase in odds of mood and anxiety disorders.53 In
a meta-analysis of cross-sectional studies in the general population,
a signiﬁcant positive association between depression and obesity in
the general population was observed, which was stronger among
women.54 Another meta-analysis evaluating the longitudinal,
bidirectional evidence of the association between depression and
obesity showed that obesity increased the risk of onset of
depression (unadjusted odds ratio (OR), 1.55), and that depression
also increased the odds for developing obesity (OR, 1.58).55
MDD may in some cases be the causal trigger leading to
obesity. This hypothesis is supported by the meta-analysis by
Luppino et al., where obesity at baseline increased the risk of
onset of depression at follow-up (unadjusted OR of 1.55).56 In a
New Zealand-based longitudinal study, adolescent girls suffering
from MDD had a twofold increase in the risk for developing
obesity in adulthood than non-depressed ones.18 Other studies
have also demonstrated that depressive symptoms during child-
hood are associated with weight gain and obesity during young
adulthood,57 and that baseline depression is associated with a 5-
year increase in visceral obesity.58
In addition to these clinical ﬁndings, obesity and MDD are
inﬂuenced by gene–environment interactions.59 In fact, there have
been association studies of obesity that identiﬁed genes that
are hypothetically involved in depression. Two of them, the
glucocorticoid receptor NR3C1 (ref. 60) and the CRH genes61 are
related to the dysregulation of the HPA. Similarly, the BDNF
Val66Met polymorphism is also associated with obesity and
depression.62
MDD AND METS
Studies have shown that the prevalence of MetS is greater in
individuals with MDD symptoms.19–22 Women with a history of
MDD have twice the chance of developing MetS than women
without such history.20 In longitudinal studies of 7–15 years of
follow-up, women with symptoms of MDD and increased tension
and anger at baseline had a higher risk of developing MetS.24
Furthermore, the risk for MetS was elevated from 1.21- to 2.12-fold
(95% conﬁdence interval (CI) 1.00–4.25) in individuals with more
severe MDD symptoms or very stressful life events.23 These cross-
sectional and longitudinal studies have shown that MDD
symptoms and stressful life events increase the risk of developing
MetS. Thus, current studies clearly support that there is a
relationship between MDD and MetS, which also appears to be
bidirectional: according to a recent meta-analysis of cross-
sectional and cohort studies, the pooled crude OR between
depression and MetS was 1.42 (95% CI 1.28–1.57). In the same
meta-analysis, the pooled adjusted OR was 1.49 (95% CI 1.19–1.89)
for MetS predicting depression risk, and 1.52 (95% CI 1.20–1.91)
for depression predicting MetS risk.63 Other meta-analyses
showed that patients with MDD had a higher MetS prevalence
(OR 1.54 (95% CI 1.21–1.97)), with higher risk for hyperglycaemia
(OR 1.33 (95% CI 1.03–1.73)) and hypertriglyceridaemia (OR 1.17
(95% CI 1.04–1.30)).64 A common pathophysiological pathway
between MDD and metabolic dysregulation involves the HPA axis,
as described below.
THE INTERPLAY BETWEEN STRESS, MDD AND OBESITY
Chronic stress is a state where there is persistent activation of the
HPA axis.65 Moreover, the HPA axis is also dysregulated in obesity,
making this axis a shared pathophysiological pathway with
MDD.65 During stress, CRH is released from the paraventricular
nucleus of the hypothalamus, stimulating the secretion of
adrenocorticotropin, which in turn stimulates cortisol secretion
from the adrenal glands.65 In order to compensate for the
resulting hypercortisolism, the negative feedback mechanism of
glucocorticoid receptors is activated and downregulates the
cortisol stress response.65 However, in MDD, an excess amount
of cortisol in circulation and the over-expression of mineralocorti-
coid and glucocorticoid receptor results in decreased negative
feedback, leading to enduring hypercortisolism.66 Cortisol facil-
itates lipid accumulation by activation of glucocorticoid receptor;
as these receptors are highly expressed in the intra-abdominal
and visceral areas, this is one of the major pathways leading to
visceral and central obesity, and consequently, metabolic
complications.65 Inﬂammation is another pathway that links
obesity to MDD,56 as both disorders are associated with the
activation of inﬂammatory pathways.56 However, studies have also
demonstrated a pro-inﬂammatory state in lean depressed
individuals, suggesting that the pro-inﬂammatory state in MDD
may not be primarily related to obesity.67 The simultaneous
activation of inﬂammatory pathways by depression and by obesity
can only be detrimental. Furthermore, increased insulin resistance,
frequently observed in obesity and in pro-inﬂammatory states,
may induce alterations in the brain and increase the risk of MDD.56
ANTIDEPRESSANTS
In 1950s, the antidepressant effects of MAOIs were ﬁrst discovered
when tuberculosis patients were treated with iproniazid.68–70
Shortly after iproniazid treatment initiation, patients experienced
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an antidepressant-like effect with elevated mood. Subsequently, it
was shown that iproniazid is a MAOI, with the ability to inhibit the
enzyme monoamine oxidase to catabolise monoamines, prevent-
ing monoamine depletion in the brain.69 Since then, it has been
hypothesised that a depletion in other neurotransmitters such as
norepinephrine, dopamine and serotonin contributes to cause
MDD.69 There are different classes of antidepressant drugs,
and, primarily, they have been known to work by modulating
neurotransmitter levels in the brain.4 Older generation antide-
pressants include MAOIs and tricyclics (TCAs),4 whereas newer
types of antidepressants have greater speciﬁcity and include
selective reuptake inhibitors (selective serotonin reuptake inhibi-
tor, SSRI), serotonin and norepinephrine reuptake inhibitors
(SNRIs), and norepinephrine and dopamine reuptake inhibitors.4
Other antidepressants include tetracyclics and serotonin antago-
nist and reuptake inhibitors.
Currently, non-selective MAOIs on the market include phenel-
zine (Nardil), isocarboxazid (Marplan) and tranylcypromine
(Parnate).68 Selective MAOIs include selegiline (Emsam) and
clorgyline.68 However, the use of such drugs declined because
of their serious side effects, such as those related to food and drug
interactions. MAOIs are used as a third or fourth line of the therapy
when other types of therapy have failed.68
The therapeutic action of TCAs is known to occur via inhibition
of serotonin and norepinephrine reuptake.71 These include
imipramine (Tofranil), amitriptyline (Elavil), nortiptyline (Allegron),
trimipramine (Surmontil), protriptyline (Concordin) and iprindole
(Prondol).72 However, TCAs have multiple nonspeciﬁc actions that
are associated with side effects.71 These nonspeciﬁc actions
include anticholinergic–antimuscarinic (M1), α-1 adrenergic antag-
onistic and antihistaminergic activities (H1).71 Furthermore, large
doses of TCAs inhibit sodium channels, leading to lethal cardiac
arrhythmias and seizures.71 For this reason, TCA antidepressants
are used with caution in patients with high risk of CVD.73–75
Moreover, TCA-induced weight gain is one of the main reasons for
the discontinuation of treatment within 1 month.76
Since the US Food and Drug Administration’s approval of
ﬂuoxetine (Prozac) in 1988, SSRIs have been the most prescribed
antidepressants on the market.77 They act by inhibiting serotonin
(5-hydroxytryptamine, 5HT) uptake. Since then, other SSRIs have
emerged in the market, and these include citalopram (Celexa),
ﬂuvoxamine (Floxyfral), paroxetine (Aropax) and sertraline
(Zoloft).78 Although SSRIs have been well tolerated by patients
because of fewer side effects than previous drug, there is still a
substantial proﬁle of adverse drug reactions, such as sexual
dysfunction, drowsiness, weight gain, dry mouth, insomnia,
fatigue, nausea, dizziness and tremors.79,80 The tolerability of a
drug can be assessed by discontinuation rates in clinical trials. The
discontinuation rate within 2 months for ﬂuvoxamine was ~ 70%,
followed by ﬂuoxetine (45%) and sertraline (40%).81–83
After the successful development of SSRIs, it was proposed that
the simultaneous action of selective noradrenaline and serotonin
reuptake could provide better efﬁcacy.84–86 Thus, antidepressant
SNRIs are as effective as TCAs, but side effects such as cardiac
arrhythmias and seizures are signiﬁcantly reduced.84–86 SNRIs
available on the market include duloxetine (Cymbalta), venlafaxine
(Effexor), desvenlafaxine (Pristiq) and milnacipran (Savella).
CLINICAL FINDINGS ON THE EFFECTS OF ANTIDEPRESSANT
USE ON BODY WEIGHT
TCA
In the study conducted by Berken et al., low to moderate doses of
the TCAs amitriptyline (150 mg per day), nortriptyline (50 mg
per day) and imipramine (80 mg per day) were associated with a
mean weight gain of 1.3–2.9 lbs per month, and the trend of
weight gain remained linear overtime.76 Furthermore, it was
suggested that the main reason for patients discontinuing
treatment was excessive weight gain.76 In more recent studies,
TCA antidepressants have been shown to increase the OR for
MetS to 2.30 (95% CI 1.21–4.36), and this was independent of
depression severity.87 In a 4-year follow-up study, the mean
weight gain in patients treated with unspeciﬁc antidepressants
was 4.3%, whereas in control subjects it was 2.5%. Moreover,
weight gain for the TCA antidepressant users was 4.7% (Table 1).88
Sussman et al. observed that during acute treatment with
imipramine, 4.9% patients signiﬁcantly gained weight; this rate
increased to 24.5% in long-term treatment.93 Nortriptyline (TCA)
was associated with an increase in BMI of 0.44 kg/m2 over a 12-
week period.94 Furthermore, 6 months of nortriptyline treatment
was associated with an increase of 0.64 kg/m2 in BMI.94
SSRIS AND SNRIS
Initially, when patients were treated acutely with SSRIs weight loss
was observed.95 Currently, SSRIs are useful for the treatment of
obese patients with binge eating disorder, given their anti-
impulsive action. However, their clinical relevance for weight loss
in these patients remains unclear. In the recently published
Endocrine Society Clinical Practice Guideline on the Pharmacolo-
gical Management of Obesity, the use of SSRIs is not listed as a
therapeutic tool.96 Despite the fact that SSRI use has been
associated with weight loss when acutely treated, a number of
studies have shown SSRIs to be associated with long-term risk of
weight gain.79,89,91,92 However, the number of long-term studies
over the period of 1 year is limited, and there is a need for studies
speciﬁcally investigating the long-term effects of SSRIs on body
weight.
Cascade et al. reported that 6% of patients using SSRIs gained
weight.79 The Canadian National Population Health Survey (NPHS)
is a longitudinal study that has found that SSRIs and the SNRI
venlafaxine use are associated with signiﬁcant weight gain.89 A
long-term comparison study investigated the effects of different
types of SSRI on weight gain in patients with panic disorder. It
showed that paroxetine, ﬂuoxetine, citalopram and ﬂuvoxamine
induced weight gain of, respectively, 8.2 ± 5.4, 5.2 ± 4.4, 6.9 ± 5.7
and 6.3 ± 4.2 kg in a 1-year period.91 Michelson et al. observed
changes in body weight during a 1-year trial period of ﬂuoxetine
treatment. The initial 12-week period was associated with weight
loss of 0.35 kg, and 50 weeks of treatment resulted in weight gain
of 3 kg.92
In a prospective 4-year follow-up study, SSRI-treated patients
had weight gain of 4.6%.88 In the study conducted by Sussman
et al., 17.9% of SSRI users experienced signiﬁcant weight gain
⩾ 7%.93 Escitalopram (SSRI) treatment resulted in an increase of
0.05 in BMI scores during the ﬁrst 12 weeks, and there was an
increase of 0.12 in BMI scores after 6 months of treatment
initiation.94
In addition to the clinical studies described above, case studies
have reported extreme weight gain in patients with SSRI
treatment.97,98 In the study conducted by Bouwer et al., treatment
with citalopram led to weight gain and carbohydrate craving in
eight out of eighteen patients. In a 4-week period, one female
patient gained 8 kg, whereas in a 5-week period one male patient
gained 9 kg.98 In another case study, a 33-year-old schizophrenic
female patient was treated with ﬂuoxetine (40 mg per day) for a 9-
month period following antipsychotic treatment with risperidone
(6 mg per day) and clorazepate (15 mg per day).97 The patient was
discontinued from ﬂuoxetine because she underwent excessive
weight gain (52 kg) accompanied with carbohydrate craving.97
Therefore, some individuals may be more sensitive to weight gain
induced by SSRIs than others.97,98
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Table 1. Clinical studies on the effects of antidepressants on body weight
Study Signiﬁcance Sample size/duration Limitation
Major depression,
antidepressant medication
and the risk of obesity89
SSRI and venlafaxine were signiﬁcantly
associated with obesity.
There was no signiﬁcant association
between TCA or antipsychotic
medications with obesity
NHPS sample (1994–2004)
n= 17 276
Confounded by prescription.
Physicians may have speciﬁcally
selected these medications for
use in patients who they
believe to be most at risk of
weight gain
MetS abnormalities are
associated with severity of
anxiety and depression and
with tricyclic antidepressant
use87
Tricyclic antidepressants increased
the odds for MetS
n= 2981 The main focus of this study is
on MetS and different levels of
depression
Long-term weight gain in
patients treated with open-label
olanzapine in combination with
ﬂuoxetine for major depressive
disorder90
Patients were treated with a combination
of olanzapine and ﬂuoxetine (OFC).
Increases in ﬂuoxetine dose were predictors
of weight gain. Long-term (76 weeks) OFC
treatment may lead to a large percentage
(56%) of patient meeting the criteria for
signiﬁcant weight gain (47%)
n= 549
Real-world data on SSRI
antidepressant side effects79
36% of patients experienced side
effects associated with SSRI.
Forty-nine patients had weight gain
n= 700 Patients
A naturalistic long-term
comparison study of selective
serotonin reuptake inhibitors
in the treatment of panic
disorder91
Weight gain
Paroxetine: 8.2± 5.4 kg
Fluoxetine:
5.2± 4.4 kg
Citalopram: 6.9± 5.7 kg
Fluvoxamine: 6.3± 4.2 kg
Duration: 1 year
n= 200
Changes in weight during
a 1-year trial of ﬂuoxetine92
12-Week treatment: –0.35 kg
50-Week treatment: +3 kg
Duration: 50 weeks
n= 395
Changes in body weight
during treatment with the
new antidepressant Nefazodone,
three SSRIs Fluoxetine, Setraline,
Paroxetine, and the tricyclic
Imipramine93
Signiﬁcant weight loss or gain was,
respectively, deﬁned as ⩽ 7 and ⩾ 7%
change in body weight from baseline.
Study 1
Acute phase trial
SSRI: 4.3% of treated patients lost weight
at any point
Nefazodone: 1.7% of treated patients lost
weight at any point
Long-term phase trial
SSRI: 17.9% of treated patients had
weight gain
Nefazodone: 8.3% of treated patients
had weight gain
Study 2
Acute phase trial
Imipramine: 4.9% of treated patients
had weight gain
Nefazodone: 0.9% of
treated had weight gain
Long-term phase trial
Imipramine: 24.5% of treated patients
had weight gain
Nefazodone: 9.5% of
treated patients had weight gain
Study 1 Acute phase trial: 6–8 weeks
n= 1036
Long-term phase trial: 16–46 weeks
n= 608
Study 2 Acute phase trial: 6–8 weeks
n= 1036
Long-term phase trial: 16–46 weeks
n= 135
TCA-induced weight gain76 TCA antidepressants
Amitriptyline, nortriptyline and imipramine
induced weight gain of 1.3–2.9 lbs per month,
and weight increased linearly overtime
n= 40
Average of 6-months treatment
Body weight gain during
nortriptyline (TCA) or
escitalopram (SSRI) treatment94
Nortriptyline
First 12 weeks: +1.22 kg, BMI score increase of 0.44
After 6 months: +1.82 kg, BMI score increase of
0.64
Escitalopram
First 12 weeks: +0.14 kg, BMI score increase of 0.05
6 Months: +0.34 kg, BMI score increase of 0.12
n= 630
12 weeks and 6 months of treatment
Weight gain associated with
tricyclic or SSRI treatment88
Average weight gain of 1.4 kg (2.5%) in the control
group and 2.5 kg (4.3%) among users of 200
deﬁned daily doses of antidepressant
n= 5537
4 years
Abbreviations: BMI, body mass index; MetS, metabolic syndrome; NHPS, National Population Health Survey; OFC, a combination of olanzapine and ﬂuoxetine;
SSRI, selective serotonin reuptake inhibitor; TCA, tricyclics.
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META-ANALYSIS STUDY
Recently, Serretti et al. performed a meta-analysis on the effects
of antidepressants on body weight.95 The study showed that acute
treatment with ﬂuoxetine and bupropion was associated with
signiﬁcant weight loss of 0.94 and 1.13 kg, respectively.95
Imipramine was associated with non-signiﬁcant weight loss of
0.2 kg, and mirtazapine was associated with signiﬁcant weight
gain of 1.74 kg.95 When considering treatment periods longer than
4 months, imipramine was associated with non-signiﬁcant weight
loss of 0.04 kg, bupropion with signiﬁcant weight loss of 1.87 kg
and ﬂuoxetine with non-signiﬁcant weight loss of 0.31 kg.95 In
contrast, mirtazapine was associated with non-signiﬁcant weight
gain of 2.59 kg (Po0.07) with upper limit of 5.41 kg.95
LIMITATIONS OF CURRENT FINDINGS
Although these previous studies described the effects of
antidepressants on body weight, there are multiple problems in
clinical observations because of the methods used. Most previous
data on antidepressant-induced weight gain were extracted from
drug trials of antidepressant medications or larger cross-sectional
observational studies investigating the broad spectrum of MDD
research. Confounding effects such as physicians speciﬁcally
selecting antidepressant medication taking into consideration
the risk of weight gain could not be eliminated.89 Moreover, as
described previously, weight gain is one of the most undesired
effects of treatment, and one of the major reasons for
discontinuing treatment within the ﬁrst 2 months of treatment
initiation.94 In most cases there was no long-term follow-up
reported that would allow us to ascertain the impact of
antidepressant treatment or exposure over the lifetime.
MECHANISM PROPOSED OF ANTIDEPRESSANT-INDUCED
WEIGHT GAIN
Central and peripheral mechanisms of appetite and feeding
behaviour regulation are complex; regulatory factors such as
neurotransmitters, neuropeptides and hormone-like peptides
have a role in orchestrating appetite, feeding behaviours and
metabolic pathways.99 In previous studies, it has been suggested
that weight gain associated with antidepressants reﬂects the action
of monoamine pathways, which include serotonergic, adrenergic,
histaminergic, cholinergic and dopaminergic receptors. The
speciﬁc mechanisms of action of different antidepressants on
weight are described below (Figure 1).
MIRTAZAPINE
Mirtazapine (SNRI) has been associated with weight gain. The
mechanism of mirtazapine involves the blockade of α2-adrenergic
receptors, together with afﬁnity for histamine H1 receptors and
low afﬁnity for dopaminergic D1 and D2 receptors.95 It has been
suggested that the histaminergic system is involved in appetite
and feeding control.100 These histaminergic cell bodies are
situated in a speciﬁc region called the tuberomammilary nucleus
of the posterior hypothalamus.100 Histaminergic receptors have
been shown to interact with orexigenic neuropeptides such as
orexin A, NPY and ghrelin.101 Anti-histaminergic effects of
mirtazapine were associated with enhanced appetite by activation
of ghrelin and NPY.95,101 Furthermore, clinical doses of mirtazapine
blocked both 5HT2 and 5HT3 receptors.99 5HT2 receptors have an
essential role in appetite, and antagonising 5HT2 results in weight
gain.99
BUPROPION
In contrast to mirtazapine, bupropion has been known to induce
signiﬁcant weight loss.95 The mechanism of action of bupropion is
determined by its effect increasing dopamine and norepinephrine
neurotransmission.95 Bupropion and its metabolites selectively
inhibit dopamine and norepinephrine reuptake pumps, and may
also alter the release of dopamine and norepinephrine; yet, it does
not induce effects on postsynaptic receptors including histamine,
α- or β-adrenergic, serotonin, dopamine receptors; it is also a weak
nicotinic acetylcholine receptor antagonist. Moreover, reduced
dopaminergic tone in the hypothalamus of obese individuals may
be reversed by bupropion by increasing the activity of the
hypothalamic melanocortin system, which is an important
component in the regulation of homeostatic energy balance.102
TCA (AMITRIPTYLINE)
The pharmacological actions of TCAs are known to be non-
selective and these results in side effects associated with
signiﬁcant weight gain. Amitriptyline has high afﬁnity for α-
adrenergic, histaminergic and cholinergic receptors.95
 5HT2C
Serotonergic 
receptors 
α1/β2 
Adrenergic 
receptors 
 H1 histaminergic 
receptors
 Muscarinic 
receptors 
 Dopaminergic 
receptors 
Amitriptyline Mirtazapine BupropionFluoxetine
Induce feedingControls 
protein/carbohydrate intake 
and appetite suppression
Weight
loss
Weight 
gain
Weight 
gain
Weightgain/
weight loss
Figure 1. Mechanism of monoamine neurotransmission in antidepressant-induced weight gain. Note: ↑ denotes increased activation; ↓
denotes decreased activation.
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SSRI (FLUOXETINE)
Fluoxetine, a SSRI, has weight-reducing effects acutely. Fluoxetine
has signiﬁcant afﬁnity for 5HT2C receptors, which have a role in
appetite suppression. In addition, fasting plasma leptin levels
(an anorexigenic adipokine) were increased in patients treated
with either imipramine or ﬂuoxetine.99,103 In an acute experiment,
ﬂuoxetine injections in obese and lean rats resulted in reduced
food intake.104 In these rats, ﬂuoxetine signiﬁcantly reduced NPY
levels in the paraventricular nucleus of the hypothalamus.104
Acute weight loss is due to regulation of the carbohydrate/protein
ingestion ratio, which is known to occur through 5HT.99 Never-
theless, it would be essential to elucidate the mechanism of long-
term effect of ﬂuoxetine on body weight, which remains unclear.99
ANIMAL MODELS OF DEPRESSION AND OBESITY
Animal models of stress and depression
In the past, different attempts have been made to develop an
animal model that mimics the clinical manifestations of MDD.105
MDD is a complex disorder, and it remains controversial whether
animal models of depression mimic the depressive state of
humans. Therefore, Willner et al. proposed that animal models of
depression should fulﬁl a set of validity criteria, which included
predictive, face and construct validities.106 Predictive validity is
based on whether the animal model shows reliable pharmacolo-
gical effects of antidepressants.107 Face validity assesses both
treatment features of chronic antidepressant therapy and
symptomatic features.107 The meaning of construct validity is
rather complex, and is deﬁned as having both behaviour and
features of depression such as 'helplessness or anhedonia'.107
Furthermore, arising evidence suggests that pathophysiological
changes in the neuroendocrine system, such as in the HPA axis
and hippocampal structural changes in the process of neurogen-
esis, may be important biomarkers to validate an animal model of
depression.105,107 According to the study conducted by Willner
et al., only a few models passed all three criteria, and these models
include chronic unpredictable stress, learned helplessness and
intracranial self-stimulation.106 For these reasons, most of these
animal models are referred as 'animal models of stress' instead of
'animal models of depression'.106
In animal models, behavioural testing has been used to screen
the antidepressant effects of drugs. The most classic tests are
known as the forced swimming test and the tail suspension test.
Both forced swimming test and the tail suspension test are based
on the despair behaviour, identiﬁed with immobility and lack of
motivation to escape, and antidepressants have been demon-
strated to reverse these behaviours.108,109 Behavioural tests that
include novelty suppressed feeding, open ﬁeld and elevated plus
maze have been used to screen anxiety-related behaviours in
animal models of depression,110,111 whereas cognitive tests, such
as the Morris water maze, have been used to assess spatial
memories and cognitive deﬁcits associated with hippocampal
atrophy.112 Furthermore, anhedonic behaviour has been tested by
the sucrose preference test.113
ANIMAL MODELS OF OBESITY
At present, there are various types of animal models of obesity.
These include spontaneous mutants such as the ob/ob and the
db/db mouse models, genetically engineered models of the Mc4r
gene and those based on environmental factors such as diet-
induced obesity (DIO).114–117
ANIMAL MODELS OF GENETIC OBESITY
Leptin is an adipocyte-derived hormone encoded by the ob
gene.115,116 About two decades ago, the discovery that a genetic
mutation in the ob gene caused leptin deﬁciency and severe
obesity showed that leptin is a critical molecule in the regulation
of energy expenditure, food intake and attenuation of adipose
mass.115,116 It was demonstrated that leptin has a high binding
afﬁnity in the hypothalamus, and it inhibited the orexigenic
hormone NPY gene expression and synthesis.118
Further along, other obesity animal models have included the
db/db model and melanocortin-4 receptor null mouse, which are
characterised by elevated leptin levels and failure to attenuate
obesity after leptin treatment, have provided the foundation for
the concept of leptin resistance and hyperleptinaemia.115,117
ANIMAL MODELS OF DIO
In 1949, animal models of DIO were initially achieved by ad libitum
feeding of a semi-liquid palatable diet.119 Since then, there has
been an extensive number of studies seeking to achieve an
optimal method for DIO using various methods. These methods
included determining the optimal composition and duration of a
diet, age and the genetic background of an animal model to
induce DIO (Table 2).119 Recently, a study conducted by Buettner
et al. concluded that the optimal condition for DIO in an animal
model involved a semi-puriﬁed high animal fat diet of 40%
of energy, with a limited amount of 3-polyunsaturated fatty acids
Table 2. Animal models of diet-induced obesity
Study High-fat diet Metabolic factors Study duration
Pagliassotti et al.122 60% of kcal from fat Plasma level of insulin, β-hydroxybutrate, mRNA level and activity of lipoprotein
lipase were higher in epididymal fat pad and lower in gastrocnemius muscle
5 Weeks
Huang et al.123 59% of kcal from fat Increased mRNA levels of leptin receptor and neuropeptide Y. Decreased
POMC mRNA level
13 Weeks
Dourmashikin et al.124 50% fat content Increased levels of leptin, insulin and lipoprotein lipase in adipose tissue.
Hyperphagia, enhanced circulating triglycerides, nonesteriﬁed fatty acids
and enhanced glucose, galanin. Increased β-hyroxyacyl-coaldehydrogenase
level in muscle
3 Weeks
Dourmashikin et al.125 45–60% fat content Elevated leptin, insulin, triglyceride, glucose, lipoprotein lipase activity in
adipose tissue
4–6 Weeks
Madsen et al.121 31.8% fat content Development of visceral obesity, hyperleptinaemia, hyperinsulinemia and
dyslipidaemia, and decrease in glucose tolerance
9 Months
Abbreviation: POMC, pro-opiomelanocortin.
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(3-PUFA), and plant oils rich in 6-PUFA and 9-PUFA.119,120 Long-term
DIO was accompanied with visceral obesity, glucose intolerance,
hyperdyslipidaemia, hyperleptinaemia and hyperinsulinaemia.121
Optimal conditions for the DIO model involve genetically
outbred environments as they provide genetic diversity, where
some animals are prone to obesity while others are resistant to
it.119 A well-established method for studying DIO in rodents
involves classifying groups of animals as 'obesity-prone' and
'obesity-resistant' based on their body weight, body weight gain
and/or body fat.119 Obesity-prone rats classiﬁed as early as after
5 days of high-fat-diet feeding already had distinguishable
characteristics of metabolic dysregulation. Lipoprotein lipase
activity, plasma leptin, triglycerides and glucose levels were all
elevated.125 At week 5, obesity-prone rats had signiﬁcantly higher
epididymal and retroperitoneal fat pad weights in comparison
with the obesity-resistant group.122 Metabolic changes included
lipoprotein lipase activities, where the activities were higher in
epididymal fat pads and lower in gastrocnemius muscles in the
obesity-prone group.122 In C57BL/6 mice, mRNA levels of leptin
receptor and NPY were elevated, whereas pro-opiomelanocortin
mRNA expression was reduced in the obesity-prone group.126
Furthermore, plasma leptin and insulin levels were elevated, and
there was increased activity of lipoprotein lipase in adipose
tissue.124 In addition, there were increased glucose, non-esteriﬁed
fatty acids, triglyceride levels in the plasma and elevated β-
hydroxyacyl-CoAdehydrogenase activity in the muscle.124
ANIMAL MODELS OF STRESS AND DIO
In animal studies, the linkage between stress and obesity remains
non-consolidated, and the degree of stress paradigm, persistency
or frequency of repeated stressors has a role in modulating body
weight. Manting et al. demonstrated that, when a high-fat diet
was given to rats, there was dysregulation in lipid metabolism.127
Moreover, when the high-fat diet was given in the presence of
chronic stress, there was exacerbation in lipid dysregulation,
where higher levels of triglycerides and total cholesterol, and
lower levels of HDL-cholesterol were observed.127 In another
study, the combination of social stress and a prolonged high-fat
diet led to consequent dysregulation in lipid metabolism,
enhanced plasma levels of non-HDLs and accumulation of
triglycerides in the intrahepatic tissue.128 On the other hand,
when a high-fat diet was given to the ﬂinder-sensitive line rat
genetic model of depression, depressive-like behaviour was
exacerbated.129 These animal studies highlight the fact that on
top of the of high-fat diet effect, stress can exacerbate metabolic
dysregulation.
ANIMAL MODELS OF ANTIDEPRESSANT AND PARADOXICAL
WEIGHT LOSS
Currently, the existing animal models suggest that TCA and SSRI
antidepressant administrations have been associated with 'para-
doxical' weight loss and reduction in food consumption (Table 3).
However, the relationship between antidepressant use, MDD and
weight gain is complex; until recently, there had not been an
animal paradigm that reproduced antidepressant-induced weight
gain as observed in the clinical setting. In recent years, a novel
animal paradigm that explains the weight trajectory of rodents
during antidepressant treatment was developed by Mastronardi
et al.130 This animal model involves stress-induced weight loss and
consumption of a high-fat diet, aiming at following the long-term
Table 3. Effects of antidepress ants on the body weight of animal models
Species Treatment/duration Proposed mechanism/pathway Effect on body weight Diet Reference
Fa/Fa
Zuker rats
Fluvoxamine (25 mg kg−1)
treatment for 7 days
SSRI induces weight loss
by increasing CRH level at
the paraventricular nucleus
of hypothalamus
Weight loss Chow diet Wieczorek et al.131
Wild-type
Ay mice
Treatment of 30–60 mg kg−1 of
milnacipran followed by food
presentation after 30 min.
Food intake measured after 1/6 h.
Study duration: 3 days
Increased hypothalamic
POMC and CART
Decreased food intake
and weight
Chow diet Nanogaki et al.132
Mice Fluoxetine treatment/48 h of fasting Decrease in body weight
and food intake with
ﬂuoxetine treatment
Chow diet Sullivan et al.133
Rats Early-life neonatal handling stress
followed by 0.25 mg kg−1 per day
of imipramine treatment from
days 60 to 120
Chronic imipramine
treatment decreased
craving for sweet pellets
Chow diet Portella et al.134
Female
rats
30 days of chronic stress (food
deprivation, restraint, forced
swimming test and ﬂashing
light stress) followed by 60 days
of ﬂuoxetine treatment
Decreased consumption of
sweet pellets with
ﬂuoxetine treatment
Chow diet Gamaro et al.135
Rats 7-day treatment of ﬂuoxetine or
imipramine 10 mg kg−1 with
repeated restraint stress, followed
by 177 days of high-fat diet
during post-stress period
Increased body weight
and absolute caloric intake
during post-stress period
Mastronardi
et al.130
Abbreviations: CART, cocaine and amphetamine-regulated transcript; CRH, corticotropin-releasing hormone; POMC, pro-opiomelanocortin.
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impact of antidepressant treatment in rodents. The novel animal
paradigm suggests that short-term antidepressant treatment and
stress, followed by a high-fat diet and long-term follow-up, has an
important role in consolidating the role of antidepressant use in
weight gain.
CONCLUSION AND FUTURE DIRECTIONS
In this review, we have discussed the relationship between MDD
and obesity. Clinical ﬁndings have suggested that obesity could
increase the risk of developing MDD, and vice versa. Several
pathways may have a role in this interaction, including neuro-
endocrine, neuroimmune and neurotropic mechanisms. Among
those, activation of the HPA axis occurs both during MDD/stress
and obesity, making it the most accepted shared common
pathophysiological pathways in both disorders. Leptin and insulin
resistance are pathophysiological mechanisms that need to be
further elucidated, along with the roles of the immune system and
neurotropic factors.
Despite the concomitant occurrence of the frequent use of
antidepressants and the high incidence of obesity in Western
societies, additional studies are required to fully test our
hypothesis that the rise in obesity rates is related at least in part
to increasing antidepressant use, and to elucidate the mechanisms
underlying antidepressant-induced weight gain. Numerous
studies have investigated the effects of different classes of
antidepressants on body weight. Previous clinical studies suggest
that TCAs amitriptyline, nortriptyline and imipramine were
associated with weight gain. Mirtazapine (SNRI) has been
associated with increased weight gain. Studies have suggested
that weight gain associated with antidepressants reﬂect the action
of monoamine pathways, which include serotoninergic, adrener-
gic, histaminergic, cholinergic and dopaminergic receptors. It has
been suggested that the mechanism behind weight gain induced
by TCAs and mirtazapine (SNRI) involves afﬁnity for histaminergic
receptors. Histaminergic receptors have been shown to interact
with orexigenic neuropeptides such as orexin A, NPY and ghrelin.
Bupropion (SNRI) has been shown to induce signiﬁcant weight
loss via selective inhibition of dopamine. On the other hand,
because of dispersion in clinical studies, the effect of SSRI on body
weight remains still unclear. Despite the fact that SSRI use has
been associated with weight loss during acute treatment, a
number of studies have shown that SSRIs may be associated with
long-term risk of weight gain. Long-term studies with very much
extended periods are needed in order to understand long-term
effects of SSRI on body weight.
In animal studies, the presence of stress in addition to high-fat
diet has been shown to exacerbate metabolic dysregulation.
However, further efforts to develop animal models to characterise
and consolidate the linkage between stress and obesity are
needed. Important factors that need to be considered in
developing animal model of stress and obesity are the degree
of stress paradigm, persistency or frequency of repeated stressors,
type of diet used and duration of the study. At present,
antidepressants have shown to induce 'paradoxical weight loss'
and reduction in food consumption in most animal models;
however, a newer paradigm shows that the combination of stress
and antidepressants followed by long-term high-fat diet results in
markedly increased weight, in excess of what is caused by high-fat
diet alone.
In this review we highlight the fact that the relationship
between antidepressant use, MDD and weight gain is complex.
We emphasise the fact that it is important to develop animal
paradigms that better mimic the clinical settings, and include
lifestyle factors such as dietary choices. Furthermore, future
studies are needed to elucidate the mechanisms underlying
depression, obesity and antidepressant-induced weight gain, and
to test the hypothesis proposed in this paper that the increasing
exposure to antidepressants, deﬁned as current or past use of
antidepressant drugs, in the context of obesogenic diets and
environments, is a contributory factor to the obesity epidemic.
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